Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
AnaCardio raises €62.5M in Series B funding at lower valuation, impacting investor KDventures' portfolio value.
PRIVATESep 30, 2026
Amount Raised
€62.5 Million
Round Type
Series B
StockholmSoftwareHealth Care
Description
AnaCardio completed a €62.5M Series B funding round, though at a lower valuation than previously anticipated. KDventures AB, an existing investor, chose not to participate in the round and will write down its stake accordingly. The write-down reflects a €30.0M (49.5%) negative adjustment to KDventures' carrying value of the investment, reducing it to approximately €30.6M. AnaCardio's ownership structure now shows KDventures at approximately 2.3% on a fully diluted basis.
Company Information
Company
AnaCardio
Location
Stockholm, Stockholm County, Sweden
About
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022.
Fundz sees it the moment AnaCardio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
StockholmSoftwareHealth Care